Effect of optimal dietary therapy upon visual function in children with long-chain 3-hydroxyacyl CoA dehydrogenase and trifunctional protein deficiency

Melanie Gillingham, Richard Weleber, Martha Neuringer, William E. Connor, Monte Mills, Sandy Van Calcar, James Ver Hoeve, Jon Wolff, Cary Harding

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The objective of this prospective cohort study was to determine if dietary therapy including docosahexaenoic acid (DHA; C22:6ω-3) supplementation prevents the progression of the severe chorioretinopathy that develops in children with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Physical, biochemical, and ophthalmological evaluations, including electroretinogram (ERG) and visual acuity by evoked potential (VEP), were performed at baseline and annually following the initiation of 65-130 mg/day DHA supplementation and continued treatment with a low-fat diet. Fourteen children with LCHAD or TFP deficiency, 1-12 years of age at enrollment, were followed for 2-5 years. Three subjects with TFP β-subunit mutations had normal appearance of the posterior pole of the ocular fundi at enrollment and no changes over the course of the study. Eleven subjects who were homozygote and heterozygote for the common mutation, c.1528G > C, had no change to severe progression of atrophy of the choroid and retina with time. Of these, four subjects had marked to severe chorioretinopathy associated with high levels of plasma hydroxyacylcarnitines and decreased color, night and/or central vision during the study. The plasma level of long-chain 3-hydroxyacylcarnitines, metabolites that accumulate as a result of LCHAD and TFP deficiency, was found to be negatively correlated with maximum ERG amplitude (Rmax) (p = 0.0038, R2 = 0.62). In addition, subjects with sustained low plasma long-chain 3-hydroxyacylcarnitines maintained higher ERG amplitudes with time compared to subjects with chronically high 3-hydroxyacylcarnitines. Visual acuity, as determined with the VEP, appeared to increase with time on DHA supplementation (p = 0.051) and there was a trend for a positive correlation with plasma DHA concentrations (p = 0.075, R2 = 0.31). Thus, optimal dietary therapy as indicated by low plasma 3-hydroxyacylcarnitine and high plasma DHA concentrations was associated with retention of retinal function and visual acuity in children with LCHAD or TFP deficiency.

Original languageEnglish (US)
Pages (from-to)124-133
Number of pages10
JournalMolecular Genetics and Metabolism
Volume86
Issue number1-2
DOIs
StatePublished - Sep 2005

Fingerprint

Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase
3-Hydroxyacyl CoA Dehydrogenases
3-Hydroxyacyl-CoA Dehydrogenase
Plasmas
Visual Acuity
Proteins
Therapeutics
Fat-Restricted Diet
Mutation
Choroid
Visual Evoked Potentials
Docosahexaenoic Acids
Bioelectric potentials
Protein Subunits
Homozygote
Heterozygote
Nutrition
Metabolites
Atrophy
Retina

Keywords

  • Chorioretinopathy
  • Docosahexaenoic acid
  • Hydroxyacylcarnitines
  • Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
  • Trifunctional protein deficiency

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of optimal dietary therapy upon visual function in children with long-chain 3-hydroxyacyl CoA dehydrogenase and trifunctional protein deficiency. / Gillingham, Melanie; Weleber, Richard; Neuringer, Martha; Connor, William E.; Mills, Monte; Van Calcar, Sandy; Ver Hoeve, James; Wolff, Jon; Harding, Cary.

In: Molecular Genetics and Metabolism, Vol. 86, No. 1-2, 09.2005, p. 124-133.

Research output: Contribution to journalArticle

@article{0b61ae0d0b80437ea26e23a1cd12c977,
title = "Effect of optimal dietary therapy upon visual function in children with long-chain 3-hydroxyacyl CoA dehydrogenase and trifunctional protein deficiency",
abstract = "The objective of this prospective cohort study was to determine if dietary therapy including docosahexaenoic acid (DHA; C22:6ω-3) supplementation prevents the progression of the severe chorioretinopathy that develops in children with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Physical, biochemical, and ophthalmological evaluations, including electroretinogram (ERG) and visual acuity by evoked potential (VEP), were performed at baseline and annually following the initiation of 65-130 mg/day DHA supplementation and continued treatment with a low-fat diet. Fourteen children with LCHAD or TFP deficiency, 1-12 years of age at enrollment, were followed for 2-5 years. Three subjects with TFP β-subunit mutations had normal appearance of the posterior pole of the ocular fundi at enrollment and no changes over the course of the study. Eleven subjects who were homozygote and heterozygote for the common mutation, c.1528G > C, had no change to severe progression of atrophy of the choroid and retina with time. Of these, four subjects had marked to severe chorioretinopathy associated with high levels of plasma hydroxyacylcarnitines and decreased color, night and/or central vision during the study. The plasma level of long-chain 3-hydroxyacylcarnitines, metabolites that accumulate as a result of LCHAD and TFP deficiency, was found to be negatively correlated with maximum ERG amplitude (Rmax) (p = 0.0038, R2 = 0.62). In addition, subjects with sustained low plasma long-chain 3-hydroxyacylcarnitines maintained higher ERG amplitudes with time compared to subjects with chronically high 3-hydroxyacylcarnitines. Visual acuity, as determined with the VEP, appeared to increase with time on DHA supplementation (p = 0.051) and there was a trend for a positive correlation with plasma DHA concentrations (p = 0.075, R2 = 0.31). Thus, optimal dietary therapy as indicated by low plasma 3-hydroxyacylcarnitine and high plasma DHA concentrations was associated with retention of retinal function and visual acuity in children with LCHAD or TFP deficiency.",
keywords = "Chorioretinopathy, Docosahexaenoic acid, Hydroxyacylcarnitines, Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, Trifunctional protein deficiency",
author = "Melanie Gillingham and Richard Weleber and Martha Neuringer and Connor, {William E.} and Monte Mills and {Van Calcar}, Sandy and {Ver Hoeve}, James and Jon Wolff and Cary Harding",
year = "2005",
month = "9",
doi = "10.1016/j.ymgme.2005.06.001",
language = "English (US)",
volume = "86",
pages = "124--133",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1-2",

}

TY - JOUR

T1 - Effect of optimal dietary therapy upon visual function in children with long-chain 3-hydroxyacyl CoA dehydrogenase and trifunctional protein deficiency

AU - Gillingham, Melanie

AU - Weleber, Richard

AU - Neuringer, Martha

AU - Connor, William E.

AU - Mills, Monte

AU - Van Calcar, Sandy

AU - Ver Hoeve, James

AU - Wolff, Jon

AU - Harding, Cary

PY - 2005/9

Y1 - 2005/9

N2 - The objective of this prospective cohort study was to determine if dietary therapy including docosahexaenoic acid (DHA; C22:6ω-3) supplementation prevents the progression of the severe chorioretinopathy that develops in children with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Physical, biochemical, and ophthalmological evaluations, including electroretinogram (ERG) and visual acuity by evoked potential (VEP), were performed at baseline and annually following the initiation of 65-130 mg/day DHA supplementation and continued treatment with a low-fat diet. Fourteen children with LCHAD or TFP deficiency, 1-12 years of age at enrollment, were followed for 2-5 years. Three subjects with TFP β-subunit mutations had normal appearance of the posterior pole of the ocular fundi at enrollment and no changes over the course of the study. Eleven subjects who were homozygote and heterozygote for the common mutation, c.1528G > C, had no change to severe progression of atrophy of the choroid and retina with time. Of these, four subjects had marked to severe chorioretinopathy associated with high levels of plasma hydroxyacylcarnitines and decreased color, night and/or central vision during the study. The plasma level of long-chain 3-hydroxyacylcarnitines, metabolites that accumulate as a result of LCHAD and TFP deficiency, was found to be negatively correlated with maximum ERG amplitude (Rmax) (p = 0.0038, R2 = 0.62). In addition, subjects with sustained low plasma long-chain 3-hydroxyacylcarnitines maintained higher ERG amplitudes with time compared to subjects with chronically high 3-hydroxyacylcarnitines. Visual acuity, as determined with the VEP, appeared to increase with time on DHA supplementation (p = 0.051) and there was a trend for a positive correlation with plasma DHA concentrations (p = 0.075, R2 = 0.31). Thus, optimal dietary therapy as indicated by low plasma 3-hydroxyacylcarnitine and high plasma DHA concentrations was associated with retention of retinal function and visual acuity in children with LCHAD or TFP deficiency.

AB - The objective of this prospective cohort study was to determine if dietary therapy including docosahexaenoic acid (DHA; C22:6ω-3) supplementation prevents the progression of the severe chorioretinopathy that develops in children with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Physical, biochemical, and ophthalmological evaluations, including electroretinogram (ERG) and visual acuity by evoked potential (VEP), were performed at baseline and annually following the initiation of 65-130 mg/day DHA supplementation and continued treatment with a low-fat diet. Fourteen children with LCHAD or TFP deficiency, 1-12 years of age at enrollment, were followed for 2-5 years. Three subjects with TFP β-subunit mutations had normal appearance of the posterior pole of the ocular fundi at enrollment and no changes over the course of the study. Eleven subjects who were homozygote and heterozygote for the common mutation, c.1528G > C, had no change to severe progression of atrophy of the choroid and retina with time. Of these, four subjects had marked to severe chorioretinopathy associated with high levels of plasma hydroxyacylcarnitines and decreased color, night and/or central vision during the study. The plasma level of long-chain 3-hydroxyacylcarnitines, metabolites that accumulate as a result of LCHAD and TFP deficiency, was found to be negatively correlated with maximum ERG amplitude (Rmax) (p = 0.0038, R2 = 0.62). In addition, subjects with sustained low plasma long-chain 3-hydroxyacylcarnitines maintained higher ERG amplitudes with time compared to subjects with chronically high 3-hydroxyacylcarnitines. Visual acuity, as determined with the VEP, appeared to increase with time on DHA supplementation (p = 0.051) and there was a trend for a positive correlation with plasma DHA concentrations (p = 0.075, R2 = 0.31). Thus, optimal dietary therapy as indicated by low plasma 3-hydroxyacylcarnitine and high plasma DHA concentrations was associated with retention of retinal function and visual acuity in children with LCHAD or TFP deficiency.

KW - Chorioretinopathy

KW - Docosahexaenoic acid

KW - Hydroxyacylcarnitines

KW - Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency

KW - Trifunctional protein deficiency

UR - http://www.scopus.com/inward/record.url?scp=26244444855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26244444855&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2005.06.001

DO - 10.1016/j.ymgme.2005.06.001

M3 - Article

C2 - 16040264

AN - SCOPUS:26244444855

VL - 86

SP - 124

EP - 133

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1-2

ER -